293 related articles for article (PubMed ID: 30651130)
1. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
Rolland V; Meyer F; Guitton MJ; Bussières R; Philippon D; Bairati I; Leclerc M; Côté M
J Otolaryngol Head Neck Surg; 2019 Jan; 48(1):4. PubMed ID: 30651130
[TBL] [Abstract][Full Text] [Related]
2. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
3. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
Madasu R; Ruckenstein MJ; Leake F; Steere E; Robbins KT
Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
[TBL] [Abstract][Full Text] [Related]
4. Protective effects of sodium thiosulfate for cisplatin-mediated ototoxicity in patients with head and neck cancer.
Ishikawa E; Sugimoto H; Hatano M; Nakanishi Y; Tsuji A; Endo K; Kondo S; Wakisaka N; Murono S; Ito M; Yoshizaki T
Acta Otolaryngol; 2015 Sep; 135(9):919-24. PubMed ID: 25861690
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients.
Viglietta V; Shi F; Hu QY; Ren Y; Keilty J; Wolff H; McCarthy R; Kropp J; Weber P; Soglia J
Invest New Drugs; 2020 Oct; 38(5):1463-1471. PubMed ID: 32157599
[TBL] [Abstract][Full Text] [Related]
6. Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial.
Duinkerken CW; de Weger VA; Dreschler WA; van der Molen L; Pluim D; Rosing H; Nuijen B; Hauptmann M; Beijnen JH; Balm AJM; de Boer JP; Burgers JA; Marchetti S; Schellens JHM; Zuur CL
Otol Neurotol; 2021 Jun; 42(5):678-685. PubMed ID: 33710154
[TBL] [Abstract][Full Text] [Related]
7. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
Freyer DR; Chen L; Krailo MD; Knight K; Villaluna D; Bliss B; Pollock BH; Ramdas J; Lange B; Van Hoff D; VanSoelen ML; Wiernikowski J; Neuwelt EA; Sung L
Lancet Oncol; 2017 Jan; 18(1):63-74. PubMed ID: 27914822
[TBL] [Abstract][Full Text] [Related]
8. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Rasch CR; Tange RA; Balm AJ; Dreschler WA
Audiol Neurootol; 2006; 11(5):318-30. PubMed ID: 16983183
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
10. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
Crabb SJ; Martin K; Abab J; Ratcliffe I; Thornton R; Lineton B; Ellis M; Moody R; Stanton L; Galanopoulou A; Maishman T; Geldart T; Bayne M; Davies J; Lamb C; Popat S; Joffe JK; Nutting C; Chester J; Hartley A; Thomas G; Ottensmeier C; Huddart R; King E
Eur J Cancer; 2017 Dec; 87():75-83. PubMed ID: 29128692
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
12. Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone: A Randomized Controlled Study.
Marshak T; Steiner M; Kaminer M; Levy L; Shupak A
Otolaryngol Head Neck Surg; 2014 Jun; 150(6):983-90. PubMed ID: 24618499
[TBL] [Abstract][Full Text] [Related]
13. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
Caballero M; Mackers P; Reig O; Buxo E; Navarrete P; Blanch JL; Grau JJ
Oncology; 2017; 93(2):75-82. PubMed ID: 28511189
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy.
Theunissen EA; Zuur CL; Józwiak K; Lopez-Yurda M; Hauptmann M; Rasch CR; van der Baan S; de Boer JP; Dreschler WA; Balm AJ
JAMA Otolaryngol Head Neck Surg; 2015 Sep; 141(9):810-5. PubMed ID: 26291150
[TBL] [Abstract][Full Text] [Related]
15. Prevention of cisplatin-induced hearing loss by administration of a thiosulfate-containing gel to the middle ear in a guinea pig model.
Berglin CE; Pierre PV; Bramer T; Edsman K; Ehrsson H; Eksborg S; Laurell G
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1547-56. PubMed ID: 21533919
[TBL] [Abstract][Full Text] [Related]
16. Are intratympanic injections of N-acetylcysteine and methylprednisolone protective against Cisplatin-induced ototoxicity?
Saliba I; El Fata F; Ouelette V; Robitaille Y
J Otolaryngol Head Neck Surg; 2010 Jun; 39(3):236-43. PubMed ID: 20470667
[TBL] [Abstract][Full Text] [Related]
17. Validation of Hearing Loss Prediction Tool for Cisplatin Chemotherapy and Radiation in Head and Neck Cancer Treatment.
Deutsch BC; Collopy C; Kallogjeri D; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2021 Feb; 147(2):182-189. PubMed ID: 33300954
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.
Konrad-Martin D; James KE; Gordon JS; Reavis KM; Phillips DS; Bratt GW; Fausti SA
J Am Acad Audiol; 2010 May; 21(5):301-14; quiz 357. PubMed ID: 20569665
[TBL] [Abstract][Full Text] [Related]
19. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Brock PR; Maibach R; Childs M; Rajput K; Roebuck D; Sullivan MJ; Laithier V; Ronghe M; Dall'Igna P; Hiyama E; Brichard B; Skeen J; Mateos ME; Capra M; Rangaswami AA; Ansari M; Rechnitzer C; Veal GJ; Covezzoli A; Brugières L; Perilongo G; Czauderna P; Morland B; Neuwelt EA
N Engl J Med; 2018 Jun; 378(25):2376-2385. PubMed ID: 29924955
[TBL] [Abstract][Full Text] [Related]
20. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
